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OBJECTIVE — Toevaluatetheimpactofreal-timecontinuousglucosemonitoring(CGM)on
glycemic control and risk of hypoglycemia in critically ill patients.
RESEARCH DESIGN AND METHODS — A total 124 patients receiving mechanical
ventilation were randomly assigned to the real-time CGM group (n  63; glucose values given
every 5 min) or to the control group (n  61; selective arterial glucose measurements according
to an algorithm; simultaneously blinded CGM) for 72 h. Insulin infusion rates were guided
according to the same algorithm in both groups. The primary end point was percentage of time
ataglucoselevel110mg/dl.Secondaryendpointsweremeanglucoselevelsandrateofsevere
hypoglycemia (40 mg/dl).
RESULTS — Percentage of time at a glucose level 110 mg/dl (59.0  20 vs. 55.0  18% in
the control group, P  0.245) and the mean glucose level (106  18 vs. 111  10 mg/dl in the
control group, P  0.076) could not be improved using real-time CGM. The rate of severe
hypoglycemia was lower in the real-time CGM group (1.6 vs. 11.5% in the control group, P 
0.031).CGMreducedtheabsoluteriskofseverehypoglycemiaby9.9%(95%CI1.2–18.6)with
a number needed to treat of 10.1 (95% CI 5.4–83.3).
CONCLUSIONS — In critically ill patients, real-time CGM reduces hypoglycemic events
but does not improve glycemic control compared with intensive insulin therapy guided by an
algorithm.
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H
yperglycemia, a frequent ﬁnding in
up to 90% of all critically ill pa-
tients, is associated with increased
morbidity and mortality (1,2). In three
monocentric studies, intensive insulin
therapy to achieve and maintain normo-
glycemia resulted in decreased morbidity
and mortality (3–5). However, in two
subsequent multicenter studies, normo-
glycemiawasnotadequatelyreached,and
the studies were stopped prematurely be-
cause of safety reasons with increased
rates of severe hypoglycemia (6,7). How-
ever, in a recent trial, intensive insulin
therapy resulted in improved short-term
outcome in pediatric intensive care; an-
other recent trial demonstrated increased
mortality among adults under intensive
glucose control (5,8). An updated meta-
analysisof26randomizedtrialsincluding
13,567 patients reported that intensive
insulin therapy had no effect on the over-
all risk of death but simultaneously re-
sulted in a sixfold increased risk of severe
hypoglycemia. Currently, there is still an
intense and conﬂicting discussion on the
difﬁculty of obtaining near-normoglyce-
mia and thereby avoiding the risk of se-
vere hypoglycemia (9). In critically ill
patients, accurate real-time continuous
glucose monitoring (CGM) might be the
best way to minimize a consistently re-
ported increased rate of severe hypogly-
cemia associated with intensive insulin
therapy and to increase effectiveness and
safety of tight glucose control.
Numerousstudiesindiabeticpatients
tested CGM devices and demonstrated
high accuracy of the CGM-derived glu-
cose values compared with blood glucose
measurements (10–12). In particular,
these devices were highly sensitive in de-
tecting rapid glucose excursions (12). Re-
cently, these CGM techniques have also
beenevaluatedincriticallyillpatientsand
have yielded similar positive results (13–
17). Mainly, subcutaneous CGM devices
have been intensely investigated (13–17).
Accuracy and reliability of a subcutane-
ous CGM device could be demonstrated
both in critically ill patients with and
without circulatory shock (16). Subcuta-
neous CGM worked equally in patients
without and with norepinephrine ther-
apy. Validity of the subcutaneous CGM
under norepinephrine therapy was fur-
thermore independent of levels of blood
glucose values, severity of illness, and pa-
tients’ BMI (16). With use of this subcu-
taneous CGM device, 99% of all
measured sensor glucose values were
within the acceptable treatment zone
according to an insulin titration grid
analysis(16).Basedontheseunderlying
data, we hypothesized that subcutane-
ous real-time CGM improves glucose
control, simultaneously reducing the
risk of hypoglycemia.
RESEARCH DESIGN AND
METHODS— The study was per-
formed in the intensive care unit (ICU) of
the Department of Medicine III at the
Medical University Hospital of Vienna,
Vienna, Austria. Patients were recruited
between June 2006 and August 2008.
Patients were eligible for inclusion in
thestudywithin24hafterICUadmission
if they were aged 18 years, intubated,
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pected to stay 48 h in the ICU after ini-
tiation of intensive insulin therapy.
Patients were not enrolled in the study if
any of the following criteria were present:
ICU stay expected to be 48 h, mechan-
ical ventilation not expected for 48 h,
arterial glucose values within the normal
range (80–110 mg/dl) before enrollment,
enrollmentinanotherstudy,andnoavail-
abilityofaCGMdeviceduringthescreen-
ing phase. The study protocol was
approved by the research ethics commit-
tee of the Medical University of Vienna.
According to the Austrian law and the
guidelines of the research ethics commit-
tee, written informed consent was ob-
tained from patients after they regained
consciousness.
Intensive insulin therapy to maintain
normoglycemia (80–110 mg/dl) was per-
formed by the nurses in all patients in-
cluded in the study. In the control group,
intensive insulin therapy was performed
strictly according to a previously de-
scribedinsulintitrationalgorithm(18).In
short,thisalgorithmisaslightlymodiﬁed
version of the algorithm used in the Leu-
ven studies (3,4). It prescribes both insu-
lin infusion rate, time of next glucose
measurement, and, in case of hypoglyce-
mia, dextrose administration depending
on glucose levels and glucose trends.
Consequently, it deﬁnes nine different
states requiring different actions, al-
though leaving space for interpretation
(for the responsible nurse) because it in-
cludes dynamic variables such as glucose
trends. In the control group, selective ar-
terial blood glucose measurements were
done according to the algorithm (18). On
the basis of these arterial blood glucose
values, nurses guided intensive insulin
therapy. A continuous intravenous insu-
lin regimen was used in all patients (insu-
lin aspart, Novo Nordisk). Nutritional
support was standardized in all patients
according to a nutritional protocol. En-
ergy requirements were calculated with
25 kcal   kg body wt
1   day
1. For every
patient included, the following data were
documented: age, sex, ICU admission
reasons, height, weight, BMI, cumulative
ﬂuid balance and insulin use during the
study period, norepinephrine therapy,
comedication including dextrose infu-
sion, length of ICU stay, and ICU and
hospital mortality. Severity of illness
was assessed by the Simpliﬁed Acute
Physiology Score (SAPS II) and the Sep-
sis-related Organ Failure Assessment
(SOFA) (19,20).
CGM
Within 24 h after ICU admission, eligible
patients were randomly assigned, in a 1:1
ratio, to the real-time CGM group or to the
control group. Responsible ICU staff was
informedaboutinclusionofpatients.Inad-
dition, a user manual for the CGM device
was placed at the bedside. In the real-time
CGM group, glucose values were given ev-
ery 5 min by the subcutaneous real-time
CGMsystemfor72h(Guardian;Medtronic
MiniMed, Northridge, CA). On the basis of
these displayed subcutaneous glucose val-
ues, nurses guided insulin therapy accord-
ingtotherecommendedinsulindoseofthe
insulin titration algorithm in the real-time
CGM group also (18). However, in the in-
tervention group, nurses were requested to
take real-time glucose readings in close in-
tervals according to clinical necessity at
their personal discretion, but at least every
2hincontrastwiththecontrolgroup.Inthe
controlgroup,simultaneouslyblindedsub-
cutaneous continuous glucose reading by
the CGM System Gold (Medtronic Mini-
Med) was performed for 72 h. These
subcutaneous glucose values were
blinded to ICU staff and were retrospec-
tively downloaded to a computer using the
MiniMed Com-Station and a special pro-
gram (MiniMed Solutions Software
CGMS Sensor MMT-7310; Medtronic
MiniMed). Stored glucose data from the
real-time CGM system (Guardian) were
also downloaded (Guardian Solutions
Software, MMT-7315 version 2.16D;
Medtronic MiniMed). The CGM system
used in both groups included the same
technology and comprised a Holter-style
sensor system, a pager-size glucose
monitor, and a disposable subcutaneous
needle-type enzymatic glucose electrode
connected to the monitor. In all patients,
the sensor was placed subcutaneously in
the lateral abdominal region using a Sen-
Serter device (Medtronic MiniMed). The
actual glucose level was displayed on the
monitorscreenonlyinthereal-timeCGM
group using the Guardian. No alarm lev-
elswereset.Theﬁrstpairofarterialblood
glucose/sensor glucose values, which was
used for initial calibration of the CGM
system, was not used for statistical analy-
sis. According to the manufacturer’s in-
struction manual, both CGM systems
were calibrated against arterial blood glu-
cose measurements four times per day
(every 5–6 h). Arterial blood glucose
measurements were obtained using an
automated blood gas analyzer (ABL 700;
Radiometer Medical, Copenhagen, Den-
mark). Subcutaneous sensors were
planned to stay in place for 72 h. The
place of insertion was inspected daily for
local irritations, bleeding, and infection.
Statistical analysis
Sample size was calculated using the
GraphPad StatMate software program
(GraphPadSoftware,SanDiego,CA).An-
ticipated proportions were compared
with a 
2 test. The anticipated proportion
was 0.57 for the control group and 0.80
for the real-time CGM group.  was 0.05
(two-tailed).Asamplesizeof120wascal-
culated for a power of 80%; 10 dropouts
werecalculated.Adropoutwasdeﬁnedas
removal of the CGM sensor within 12 h
after insertion.
Data are presented as means  SD or
as absolute and relative frequency as ade-
quate. Baseline data were compared quali-
tativelytoassesssuccessfulrandomization
and quantitatively by t tests or Fisher’s
exact tests as appropriate. The primary
end point was percentage of time at a glu-
cose level 110 mg/dl. This variable was
normally distributed; therefore, a t test
was used to test the null hypothesis of no
difference. Secondary end points were
mean glucose level, median time from
start of intensive insulin therapy to
achievement of normoglycemia, inci-
dence of hypoglycemia (deﬁned as glu-
cose level 40 mg/dl), and percentage of
time at a glucose level 150 mg/dl. The
effect of the intervention versus standard
therapy was estimated as risk ratio with
95% CI. The Fisher exact test was used to
test the null hypothesis of no effect.
For subgroup analyses, stratum-
speciﬁc effects of the intervention versus
control on the primary end point were
calculated. To assess differences between
subgroups, P values for interaction by us-
ing linear regression models including in-
teraction terms of the group allocation
subgroup variable were calculated.
For data management and analysis,
MS Excel for Windows and STATA (re-
lease9.0forMac;StataCorp.,CollegeSta-
tion, TX) were used. Two-sided P  0.05
was generally considered statistically
signiﬁcant.
RESULTS— Figure 1 shows the trial
proﬁle. Baseline demographics, patients’
characteristics at ICU admission, and rea-
son for ICU admission did not differ sig-
niﬁcantly between both groups (Table 1).
Groupswerewellmatchedwithrespectto
comedicationthatcouldpotentiallyinﬂu-
ence blood glucose (hydrocortisone 25
vs. 30 patients, P  0.4754; propofol 34
Online glucose monitoring in the critically ill
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rine39vs.34patients,P0.278;enteral
nutrition 57 vs. 59 patients, P  1.0; par-
enteral nutrition 4 vs. 4 patients, P  1.0;
control group vs. real-time CGM group,
respectively).Dropouts(sensortime12
h) did not occur. In nine patients, sensors
wereaccidentallyremovedafter12–48h.
Datafortheseninepatientswereanalyzed
until accidental removal of sensors. Table
2 shows blood glucose control in both
treatmentgroups.Theprimaryendpoint,
percentage of time at 110 mg/dl, and
the secondary end points, mean sensor
and blood glucose levels, as well as per-
centage of time at 150 mg/dl, were not
different in either groups. Baseline glu-
cose values, time to reach the target glu-
cose value of 110 mg/dl, and insulin dose
during the study period also were not dif-
ferent. Rate of hypoglycemia was signiﬁ-
cantly lower in the real-time CGM group
than in the control group (1.6 vs. 11.5%,
P  0.0312). Relative risk reduction for
severe hypoglycemia is 86% (95% CI 21–
98%) using real-time CGM. This denotes
an absolute risk difference of 9.9% (1.2–
18.6) and a number needed to treat of
10.1 (5.4–83.3). All patients with hypo-
glycemic events just experienced one ep-
isode of hypoglycemia except one patient
in the control group, who experienced
twoepisodes(ondays2and3ofthestudy
period).Glucosemeasurementswereper-
formed 1,228 times in the control group.
Glucose readings of the real-time CGM
system were taken 1,772 times. Accord-
ing to the insulin therapy algorithm, the
glucose measurements in the control
group and glucose readings in the real-
time CGM group were distributed (in the
algorithm-deﬁned states) in the following
way: glucose 140 mg/dl: 118 glucose
measurements vs. 221 glucose readings,
P  0.017; glucose range 110–140 mg/dl:
32 glucose measurements vs. 98 glucose
readings, P  0.0002; approaching target
range number 1: 117 glucose measure-
ments vs. 155 glucose readings, P 
0.5049;approachingtargetrangenumber
2:226glucosemeasurementsvs.367glu-
cose readings, P  0.1274; steady in the
target range: 585 glucose measurements
vs.780glucosereadings,P0.0574;de-
creasing steeply: 22 glucose measure-
ments vs. 57 glucose readings, P 
0.0223; glucose range 60–80 mg/dl: 90
glucose measurements vs. 57 glucose
readings, P  0.0001; glucose range
40–60 mg/dl: 32 glucose measurements
vs. 36 glucose readings, P  0.3618; and
glucose 40 mg/dl: 6 glucose measure-
ments vs. 1 glucose reading, P  0.0428.
Glucose measurements/readings are given
as control group versus real-time CGM
group, respectively.
Dextrose 33% was administered one
time in the real-time CGM group and six
timesinthecontrolgroup.Intwopatients
in the control group, hypoglycemic
events remained unrecognized and were
only recorded by the blinded CGM. In
these two patients, blinded CGM re-
corded a short hypoglycemic event after
an antihypoglycemic action of the nurse
(stopping of the intravenous insulin, as-
surance of glucose intake), whereas the
next blood glucose measurement (after
1 h) already showed an increased blood
glucose value.
Subgroup analysis revealed a signiﬁ-
cant beneﬁt concerning the primary end
point (percentage of time at 110 mg/dl)
from real-time CGM for patients with a
SOFA score 11 (64.4 vs. 54.7%, P 
0.025)andforpatientswithapositiveﬂuid
balance6,000mlduringthestudyperiod
(62.7vs.51.9%,P0.031).Differencesfor
all subgroups are given in supplementary
FigureA(availableinanonlineappendixat
http://care.diabetesjournals.org/cgi/content/
full/dc09-1352/DC1). Local complica-
Figure 1—Trial proﬁle. IIT, intensive insulin therapy; MRI, magnetic resonance imaging.
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occur.
CONCLUSIONS — Management of
hyperglycemia in critically ill patients has
been one of the most controversial topics
inintensivecaremedicineforthepastfew
years (9). Although it is generally ac-
cepted that stress hyperglycemia is asso-
ciated with increased morbidity and
mortality, it is still uncertain whether
tightglycemiccontrolisbeneﬁcialoreven
harmful for critically ill patients (1,2,6–
8). Irrespective of the selected blood glu-
cose target range, in all randomized
clinical studies, the predeﬁned target
range was not reached in the majority of
patients, which resulted in an increased
rate of severe hypoglycemia (6–8). Thus,
real-time CGM seems to be the optimal
approachtoincreasetheeffectivenessand
safety of intensive insulin therapy in crit-
ically ill patients. However, in our pro-
spective randomized study, glucose
control could not be signiﬁcantly im-
proved using real-time CGM. Compared
withthatinpreviousstudies,glucosecon-
trol in our control group was well main-
tained, possibly offering little space for
improvement (13). This fact may be due
to the long-term clinical experience with
tightglycemiccontrolinourICU(16,18).
Nevertheless, sample size calculation was
based on the assumption that real-time
CGM would lead to a 23% improvement
in glucose control. This goal was deﬁ-
nitely not met. One obstacle may be im-
perfect adherence to the order to check
online glucose values at least every 2 h.
We attached great importance to this or-
der; however, a nurse-to-patient ratio of
1:2 in our ICU and the pressure of work,
especiallyduringfornightshift,mayhave
weakened adherence to the order. Al-
though more glucose readings in the real-
time CGM group led to a remarkable
insulin infusion increase (more readings
of 140 mg/dl and between 110 and 140
mg/dl)inthehyperglycemicrangethanin
the control group, more glucose readings
also required a remarkable reduction in
the insulin infusion rate (more readings
regarded as decreasing steeply), resulting
in a lack of beneﬁt concerning glucose
control.
Anotherreasonmaybetheomnipres-
ent fear of hypoglycemic events. This fear
seems to be justiﬁed because the rate of
hypoglycemia was 11.5% in the control
group, and even blinded CGM revealed
unrecognized hypoglycemic events,
which were not detected by selective ar-
terial blood glucose measurements ac-
cording to the insulin titration algorithm.
Real-time CGM, however, reduced
severe hypoglycemic events signiﬁcantly.
In the real-time CGM group, more glu-
cosereadingswereregardedasdecreasing
steeply according to the algorithm. Ac-
cording to our algorithm, this requires a
large reduction (by half) in the insulin in-
fusionrateandanearly(1-h)nextglucose
measurement/reading. In the control
group, however, more glucose values be-
tween60and80mg/dloccurred.Accord-
ing to the algorithm, glucose values
between 60 and 80 mg/dl only required a
reduction of the insulin infusion rate by
0.5IU/h(no1-hglucosemeasurementor-
der). These two facts may have contrib-
uted to the prevention of hypoglycemic
events in the real-time CGM group and
led to hypoglycemic events in the control
group.Glucosetrendsarerecognizedeas-
ily with the real-time CGM system be-
cause glucose values (mean of every 5
Table 1—Baseline characteristics
Real-time CGM Control P
n 63 61
Admission reason (patients in category)
Respiratory failure 15 (24) 13 (21) —
Cardiopulmonary resuscitation 12 (19) 15 (25) —
Sepsis/septic shock 13 (20) 12 (20) —
Heart failure 8 (13) 11 (18) —
Neurological disease/coma 9 (14) 4 (7) —
Pulmonary embolism 3 (5) 3 (5) —
Gastrointestinal bleeding/acute liver
failure 3 (5) 2 (4) —
History of diabetes 12 (19) 12 (20) 1
Age (years) 58  15 62  16 0.168
Sex (female/male) (20/43) (26/35) 0.265
BMI (kg/m²) 27.1  5.1 26.6  3.8 0.501
SAPS II 59  16 58  17 0.891
SOFA score 11.4  3.8 10.82  3.9 0.400
Baseline glucose value (mg/dl) 138.0  21.4 140.8  23.1 0.465
Baseline blood pH 7.39  0.08 7.37  0.11 0.280
Baseline lactate 1.32  0.49 1.49  1.07 0.260
Fluid balance (ml, study period) 6,475 (2,585–8,943) 5,356 (1,183–9,440) 0.567
Baseline systolic blood pressure
(mmHg) 124  24 123  22 0.881
Baseline diastolic blood pressure
(mmHg) 62  12 60  11 0.272
Baseline norepinephrine dose
(	g   kg
1   min
1) 0.12  0.08 0.15  0.16 0.956
Data are n (%), means  SD, or median (interquartile range), unless otherwise stated.
Table 2—Primary and secondary end points
Real-time CGM Control P
n 63 61
Mean sensor glucose (mg/dl) 105.8  18.1 110.6  10.4 0.076
Mean blood glucose (mg/dl) 113.2  14.3 114.0  11.0 0.731
Time of glucose 110 mg/dl (%) 59.0  20.4 55.0  18.0 0.245
Time of glucose 150 mg/dl (%) 94.2  7.9 92.9  8.4 0.395
Time to reach 110 mg/dl (min) 150 (48–275) 118 (45–240) 0.557
Rate of hypoglycemia (% of patients) 1.6 11.5 0.031
Insulin (IU/72 h, study period) 104  78 110  52 0.320
Length of stay 17.4  14.4 16.8  12.2 0.785
ICU mortality (%) 22 26 0.677
Hospital mortality (%) 33 31 0.849
Data are means  SD, median (interquartile range), or %.
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monitor. The reduction of severe hypo-
glycemic events was signiﬁcant with a
number needed to treat of 10 using the
real-time CGM system. Real-time CGM is
thereforeasuitablesystemtoimprovepa-
tients’safetywhilepracticingintensivein-
sulin therapy. This point is of major
importance because high rates of (recog-
nized) severe hypoglycemia have been
criticized in all studies concerning tight
glycemic control (3–8). The most recent
multicentric clinical trial indicated that
tight glycemic control may even have
harmful effects, possibly mediated by an
increased rate of hypoglycemia (8). The
results of our study suggest that the neg-
ative effects of intensive insulin therapy
might also be caused by up-to-now unrec-
ognized hypoglycemic events. Real-time
CGM offers the possibility of performing
clinicaltrialsusingintensiveinsulintherapy
without increased rates of severe hypogly-
cemia because it is able not only to detect
them but also to prevent them.
The use of real-time CGM was not
able to shorten the time to reach blood
glucose values 110 mg/dl in our study.
However, the time to reach target blood
glucose levels in our study, which was
118 and 150 min, respectively, is re-
garded as adequate from our point of
view. An even more rapid achievement
of the target range increases the risk of
overshooting, resulting in both more hy-
poglycemic and consequently more hy-
perglycemic events. Because high glucose
variability has also been shown to be as-
sociatedwithhighermortalityincritically
ill patients, overshooting insulin thera-
pies and too rapid glucose changes might
be avoided (21).
Subgroup analysis showed a signiﬁ-
cant beneﬁcial effect on the primary end
point in the most severely ill patients. In
addition, although not statistically signif-
icant, patients in the real-time CGM
groupwithSAPSII59hadahigherper-
centage of time with a glucose level 110
mg/dl. In one of our previous studies, we
could demonstrate that tight glycemic
control was less successfully reached in
moreseverelyillpatients(16).Inthisspe-
cial group of patients in the ICU, blood
glucose levels may be more ﬂuctuant and
delicate. Therefore, we assume that the
sickest patients in the ICU in particular
may beneﬁt from the real-time CGM.
Validation studies of subcutaneous
CGMhaveshownaccuracyandreliability
not only in patients with diabetes but also
in patients with cystic ﬁbrosis and criti-
cally ill patients (10–13,16,17,22,23).
Several outcome studies using real-time
CGM in patients with type 1 diabetes and
pregnant women with diabetes indicated
promising results concerning improved
glucose control and also increased safety
for patients by reducing hypoglycemic
events (24,25). Therefore, more research
into CGM to improve ease of use and
safety of intensive insulin therapy for crit-
ically ill patients is needed.
A limitation of this study is the rela-
tively small number of patients included.
The number was adequately calculated
for our primary end point; however,
many more patients are required to assess
possible beneﬁts of CGM on morbidity
and mortality. Another aspect may be the
short duration of our intervention, which
was limited to one sensor lifetime of 72 h.
The monocentric design of the study
may also be a limitation because of the
long-term experience of all groups of
healthprofessionalsinourICU,whohave
been performing intensive insulin ther-
apyforyearsinacooperativeandsuccess-
ful way (18). In other settings with
personnel less experienced and less suc-
cessful in intensive insulin therapy, the
beneﬁts from the application of real-time
CGM may be even greater.
A further limitation may be the use of
the same insulin titration algorithm with
respecttotheinsulininfusionrateinboth
the control group and the real-time CGM
group. Future studies may beneﬁt from
the development of a new algorithm, in-
cluding guidelines for insulin adjustment
and readjustment, guidelines for the next
use of CGM data, and guidelines for off-
settingtrendsversusreactingtomeasured
results when using real-time CGM.
The results of our study indicate that
real-time CGM increases the safety of tight
glycemic control in critically ill patients by
signiﬁcantly reducing severe hypoglycemic
events. However, real-time CGM could not
improveglucosecontroldeﬁnedaspercent-
age of time at 110 mg/dl.
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